Nothing Special   »   [go: up one dir, main page]

AR059338A1 - N-fenilbenzotriazolilo como inhibidores de c-kit - Google Patents

N-fenilbenzotriazolilo como inhibidores de c-kit

Info

Publication number
AR059338A1
AR059338A1 ARP070100490A ARP070100490A AR059338A1 AR 059338 A1 AR059338 A1 AR 059338A1 AR P070100490 A ARP070100490 A AR P070100490A AR P070100490 A ARP070100490 A AR P070100490A AR 059338 A1 AR059338 A1 AR 059338A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
cyclyl
optionally substituted
independently
Prior art date
Application number
ARP070100490A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AR059338A1 publication Critical patent/AR059338A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos, y composicion farmacéutica, utiles en el tratamiento del cáncer. Reivindicacion 1: Un compuesto representado por la formula (1):o su sal o N-oxido farmacéuticamente aceptable, donde R12 es -NR3COR31, -NR3CONR32R31, -NR3SO2R31, -CO2R3, - CO2H, -alquil C0-8NR3R31, -aIquil C0-8SO2NR3R31, -aIquil C0-8SO2R3, heterociclilo, hetarilo, o -CONR3R31; R11, R13 y R14 son independientemente F, CI, alquilo C0-3, o alcoxi C0-8; Y es como se muestra en las formulas (2) y (3), Ra y Rb son cada uno independientemente alquilo C0-8 o cicloalquilo C3-8, o Ra y Rb tomados junto con el C al cual están unidos forman un anillo de 3-10 miembros saturado o parcialmente insaturado que contiene opcionalmente 0-4 N, O, S, SO, o SO2 en los nodos del anillo, siempre que ningun átomo de N, O u S sea colocado en forma adyacente uno del otro en los nodos del anillo; m es 2, 3, 4 o 5; n es 1,2, 3, 4 o 5; Z es un grupo ciclilo o heterociclilo, opcionalmente sustituido con 1-5 sustituyentes independientes halogeno, -NR34R35, -NR34COR35, -NR34C(O)OR35, -NR34SO2R35, -OR34, -SR34, -SO2R34, -SO2NR34R35, -C(O)OR34, -CO2H, -CONR34R35, alquilo C0-8, alquenilo C2-8, alquinilo C2-8, CN, CF3, NO2, oxo, ciclilo o heterociclilo; R3, R31, R32, R33, R34 y R35 son independientemente alquilo C0-8 opcionalmente sustituido con un sustituyente heterociclilo, CHF2, u OH; -alquil C0-8-cicloalquilo C3-8, CF3, -alquil C0-8-O-alquilo C0-8, -alquil C0-8-Nalquil C0-8-alquilo C0-8, -alquil C0-8-S(O)0-2- alquilo C0-8, o heterociclilo opcionalmente sustituido con un sustituyente alquilo C0-8, ciclilo o ciclilo sustituido; o bencilo opcionalmente sustituido con -SO2-NH2.
ARP070100490A 2006-02-06 2007-02-06 N-fenilbenzotriazolilo como inhibidores de c-kit AR059338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77151906P 2006-02-06 2006-02-06

Publications (1)

Publication Number Publication Date
AR059338A1 true AR059338A1 (es) 2008-03-26

Family

ID=38110706

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100490A AR059338A1 (es) 2006-02-06 2007-02-06 N-fenilbenzotriazolilo como inhibidores de c-kit

Country Status (4)

Country Link
US (1) US20070232669A1 (es)
AR (1) AR059338A1 (es)
TW (1) TW200740776A (es)
WO (1) WO2007092403A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392313B1 (en) * 2001-05-16 2007-04-18 Novartis AG Combination comprising n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido|-2-methylphenyl -4-(3-pyridyl)-2pyrimidine-amine and a biphosphonate
GB201321740D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CR20220303A (es) 2019-12-24 2022-09-02 Gilead Sciences Inc Compuestos moduladores de la diacilglicerol quinasa
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4245756B1 (en) 2022-03-17 2024-10-09 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82395C2 (en) * 2003-08-21 2008-04-10 Оси Фармасьютикалз, Инк. N-substituted benzimidazolyl c-kit inhibitors
CN1839130A (zh) * 2003-08-21 2006-09-27 Osi制药公司 N－取代的吡唑基－酰胺基－苯并咪唑基的c－kit抑制剂

Also Published As

Publication number Publication date
TW200740776A (en) 2007-11-01
WO2007092403A1 (en) 2007-08-16
US20070232669A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR052419A1 (es) Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
CO6220853A2 (es) Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
JP2016506962A5 (es)
AR045389A1 (es) Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
EA201290260A1 (ru) Бензимидазол-имидазольные производные
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc

Legal Events

Date Code Title Description
FB Suspension of granting procedure